With an array of expensive gene therapies recently approved by the Food and Drug Administration, health plans have been scrambling to develop clinical coverage guidelines that balance cost and efficacy. Employer-sponsored groups have also begun carving such treatments out of their plan benefit design and placing their management and funding in the hands of patient assistance programs. In extreme cases, plan members have been sent abroad to obtain FDA-sanctioned supplies of their life-saving drugs.
This webinar will offer updates and legal strategies for dealing with these costly but promising treatments.
Topics
- Recently approved gene therapies and their pricing
- Compliance issues associated with clinical coverage guidelines, plan carve-outs, patient assistance programs and medical tourism
- Strategies for successfully navigating legal and policy concerns
Presenters
Peter J. Enko, Partner
James Rodenberg, Senior Counsel
Who Should Attend
General counsel, company presidents and officers, and pharmacy compliance professionals.
Continuing Education Credit
This program is pending approval for Colorado, Illinois, Iowa, Missouri, Nebraska, Tennessee, Texas and Wisconsin continuing legal education credit.
Questions? Contact Emily Kenyon at 816.983.8776.